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Reply to: HCC and liver disease risk in homozygous
PNPLA3 p.I148M carriers approach monogenic inheritance
on these data, the use of PNPLA3 genotyping alone to positively
predict risk of HCC is unlikely to be tenable. However, even in this
HCC-enriched dataset, the negative predictive value was substan-
tially greater, both within the NAFLD vs. NAFLD-HCC comparison
and the NAFLD-HCC vs. unselected background population com-
parison, and so it may be that knowledge of PNPLA3 rs738409
genotype has utility to select out those individuals least likely
to develop HCC and therefore least likely to beneﬁt from surveil-
lance. As Krawczyk et al. suggest, studies addressing the interac-
tion between PNPLA3 and HFE in determining HCC risk would be
of great interest. Given the increasing prevalence of NAFLD-HCC
and consequent clinical need for improved risk-stratiﬁcation care
pathways [10], we would also suggest that large, prospective
studies are needed urgently to validate our ﬁndings and to deter-
mine the utility and health-economic merits of a multi-factorial
risk stratiﬁcation that incorporates PNPLA3 rs738409 genotype
along with other recognised risk factors for HCC.
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Letters to the EditorTo the Editor:
We read with interest the thought-provoking letter from
Krawczyk et al. [1] in response to our recent publication in the
Journal of Hepatology describing the strong genetic association
between the PNPLA3 rs738409 (C>G, p.I148M) variant and the
development of NAFLD-associated hepatocellular carcinoma
(HCC) [2]. We agree that the observed magnitude of effect is
striking: comparison of genotype frequencies between a
NAFLD-HCC patient cohort and an unselected UK general popula-
tion sample (the MRC/Wellcome Trust UK 1958 Birth Cohort)
demonstrated a 12-fold increased risk of HCC [OR 12.19; 95% CI
6.89–21.58; p <0.0001] for rs738409 minor (G) allele homozy-
gotes relative to C-allele homozygotes [2]. Krawczyk et al.
compare the effect of PNPLA3 to the monogenic condition, hered-
itary haemochromatosis due to HFE rs1800562 (A>G, p.C282Y).
As their detailed comparison demonstrates, carriage of either
variant confers a similar risk of HCC [1].
Although statistical techniques to assess proportion of vari-
ability explained by genetic variations are imperfect [3], our data
indicates a Population Attributable Risk (PAR) of PNPLA3
rs738409 for HCC of 55% and an AUROC of 0.68 attributable to
this variant [2]. Further supporting the independent role of
PNPLA3 rs738409 as a risk factor for HCC, it is telling that other
genetic variants that are strong modiﬁers of NAFLD severity
and ﬁbrosis progression such as TM6SF2 [4,5], do not appear to
confer an additional, independent increased risk of HCC [4]. We
agree with Krawczyk et al. that PNPLA3 is an important genetic
risk factor for liver disease. For the moment, we would however
caution against a move towards considering ‘‘PNPLA3-associated
NAFLD’’, or by extension ‘‘PNPLA3-associated HCC’’, as distinct,
monogenic conditions analogous to HFE in haemochromatosis
but rather suggest that PNPLA3 should be considered a strong
modiﬁer within a complex, polygenic disease trait that is subject
both to genetic and substantial environmental inﬂuence (e.g. due
to dietary factors and the intestinal microbiota [6]).
Given the mounting evidence of an association between
PNPLA3 and HCC [7,8], it is timely to consider the clinical utility
of PNPLA3 genotyping to assist in patient risk stratiﬁcation. It
has been suggested that, assuming a sensitivity of 80%, an odds
ratio of >50 is required to control false-positive rates to an
acceptable level of <10% [9]. A re-analysis of the data from Liu
et al. [2] to assess sensitivity/speciﬁcity is shown in Table 1. BasedTable 1. Reanalysis of the data from Liu et al. [2] focusing on clinical utility of PNPLA3 genotype testing in HCC risk prediction.
Cohorts (n) Genotype comparison Sensitivity Specificity PPV* NPV*
NAFLD-HCC (100) vs. 
NAFLD cohort (275)
GG vs. CC 51% 79% 47% 82%
CG/GG vs. CC 72% 45% 32% 82%
NAFLD-HCC (100) vs.
background UK Popn (1476)
GG vs. CC 51% 92% 28% 97%
CG/GG vs. CC 72% 59% 10% 97%
CI, conﬁdence interval; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; N, number; OR, odds ratio; p, protein. Risk allele frequencies according to
http://www.ncbi.nlm.nih.gov/snp/.
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Chronic kidney disease (CKD) and NAFLD: Time for awareness
and screening
To the Editor:
We read with interest the article by Allen et al. reporting
on the high prevalence and associated mortality of chronic
kidney disease (CKD), in patients who had undergone liver
transplantation [1].
We believe a thorough interpretation of these ﬁndings, which
are consistent with recent liver transplant literature, should take
into account the evolving aetiological spectrum of liver disease in
both patients candidate for liver transplantation as well as in
those with milder stage disease [2]: in either case, non-alcoholic
steatohepatitis (NASH) is as an emerging risk factor for renal dys-
function, as compared with other aetiologies of cirrhosis. An anal-
ysis of the United Network Organ Sharing (UNOS) database,
during the years 2002–2011, shows NASH-related cirrhosis as
an increasing indication for simultaneous liver-kidney transplan-
tation (SLKT) [3]. A concerning observation was the reduced
5-year liver graft, kidney graft, and patient survival in NASH
patients in comparison to transplantation for other causes of cir-
rhosis (HR of 2.50 (95% CI 1.10–5.80), 2.30 (1.10–5.10), and 2.20
(1.02–5.79) respectively), for loss of liver transplant, loss of kid-
ney graft, and death. These ﬁndings are consistent with European
data suggesting NASH as a risk factor for severe renal impairment
after liver transplantation; Houlihan et al. [4] reported more rapid
loss of renal function in patients receiving a liver transplant for
NASH-related cirrhosis in comparison to other aetiologies of cir-
rhosis (OR for incident CKD in NASH vs. controls of 2.43 (95% CI
1.05–5.63)) 2 years after liver transplantation, independent of
BMI, diabetes, hypertension, hepatocellular carcinoma, and
tacrolimus levels. Remarkably, 35% of patients transplanted for
NASH-related cirrhosis progressed to stage 3b-4 CKD within
2 years after liver transplantation, compared to 10% of patients
transplanted for other aetiologies of cirrhosis.
The evidence connecting NAFLD to CKD is also emerging in the
general population: we recently subjected studies, assessing the
association of NAFLD with CKD, to meta-analysis [5], which
included 33 studies (63,902 participants, 16 population-based
and 17 hospital-based, 20 cross-sectional and 13 longitudinal).
For 20 studies, individual participant data were obtained and
NAFLD was deﬁned by liver histology in 13 studies (2205 partic-
ipants). NAFLD was associated with an increased prevalence (OR
2.12, 95% CI 1.69–2.66) and incidence (HR 1.79, 95% CI 1.65–1.95)
of CKD. In non-cirrhotic biopsy-proven NAFLD patients, NASH
was associated with a higher prevalence (OR 2.53, 95% CI 1.58–
4.05) and incidence (HR 2.12, 95% CI 1.42–3.17) of CKD than
simple steatosis. Similarly, NAFLD with advanced ﬁbrosis was
associated with a higher CKD prevalence (OR 5.20, 95% CI 3.14–
8.61) and incidence (HR 3.29, 95% CI 2.30–4.71) than NAFLD with
milder ﬁbrosis stages. Remarkably, the severity of NAFLD was
positively associated with CKD stages, with NASH and advanced
ﬁbrosis conferring a greater risk of developing stage 5 CKD (renal
failure) than simple steatosis and milder ﬁbrosis stages,
respectively.
In all analyses, the magnitude and direction of effects
remained unaffected by diabetes status (present vs. absent) and
after adjustment for other traditional risk factors for CKD
(including age, obesity, metabolic syndrome components,
smoking, hypertension, race).
The prevalence of CKD, as well as NAFLD, is continuously
rising in concert with the epidemic of its risk factors, including
diabetes, obesity and metabolic syndrome. Although early recog-
nition and treatment of CKD have been shown to reduce the stag-
gering cost of CKD and related hospitalizations [6], CKD often
goes unrecognized, and in the Third National Health and Nutri-
tion Survey (NHANES III), among all individuals with moderately
decreased GFR (stage 3 CKD), the awareness approached 8.2% [7].
Since current therapeutic options to reverse CKD in liver
transplant recipients are limited, the ﬁndings discussed above
emphasize the need for practicing hepatologists to recognize
early CKD in chronic liver disease patients and in NAFLD in par-
ticular, to optimize the management of these patients by delaying
renal disease progression. From a therapeutical stand-point,
promising preliminary evidence from randomized trials suggest
several available pharmacological classes provide incremental
beneﬁts on renal disease progression over others, with statins
[8] and angiotensin receptor blockers slowing renal function
decline and ameliorating proteinuria [9], in addition to the
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